Jane Street
IPHA

Jane Street’s Innate Pharma IPHA Stock Holding History

Jane Street’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.5K Sell
43,365
-49,388
-53% -$80.6K ﹤0.01% 10933
2025
Q4 		$162K Buy
+92,753
New +$179K ﹤0.01% 9877
2024
Q2 		– Sell
-14,554
Closed -$41.9K – 9770
2024
Q1 		$41.9K Buy
+14,554
New +$38.1K ﹤0.01% 8787
2022
Q2 		– Sell
-37,736
Closed -$127K – 10205
2022
Q1 		$127K Buy
37,736
+23,012
+156% +$84.9K ﹤0.01% 9330
2021
Q4 		$67K Sell
14,724
-9,706
-40% -$51.6K ﹤0.01% 9414
2021
Q3 		$151K Buy
+24,430
New +$105K ﹤0.01% 9060

Other funds holding IPHA

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Jane Street's IPHA Position: Q1 2026 in Review

Jane Street reduced its Innate Pharma (IPHA) stake by 53% in Q1 2026, selling an estimated $80.6K and leaving 43,365 shares worth $55.5K. The position accounts for ﹤0.01% of the portfolio, ranked #10933.

Jane Street first reported a position in IPHA in Q3 2021 and has held it in 6 quarters since. The position peaked at $162K in Q4 2025. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

  • Jane Street held 43,365 shares of Innate Pharma worth $55.5K as of Q1 2026.
  • Jane Street sold 49,388 Innate Pharma shares in Q1 2026, an estimated $80.6K.
  • Innate Pharma made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10933 holding.
  • Jane Street first reported a position in Innate Pharma in Q3 2021 and has held it in 6 quarters since.
  • Jane Street's Innate Pharma position peaked at $162K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.